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Summary
Objective: To determine whether overexpression of glutamine: fructose-6-phosphate amidotransferase (GFAT) in synoviocytes will
antagonize the response to interleukin-1 (IL-1) of chondrocytes and synovial fibroblasts in co-culture.
Methods: Synovial fibroblasts from the rat were transduced by an adenovirus carrying the cDNA for GFAT and then co-cultured with rat
chondrocytes encapsulated in alginate beads. Following challenge with 1, 5, or 10 ng/ml of IL-1 for 24 h, proteoglycan synthesis by the
chondrocytes was determined by incorporation of Na235SO4. Production of nitric oxide (NO) and prostaglandin E2 (PGE2) were monitored by
assay of conditioned medium from the co-culture.
Results: IL-1 treatment of untransduced-synoviocyte/chondrocyte co-cultures resulted in markedly decreased proteoglycan synthesis by
the chondrocytes, and increased NO and PGE2 levels in the culture medium. In contrast, adenovirus-mediated transfer of GFAT in
synoviocytes prevented both the decrease in chondrocyte proteoglycan synthesis and increases in NO and PGE2 provoked by IL-1.
Conclusions: Our study suggests that in a synoviocyte/chondrocyte co-culture system, overexpression of GFAT by synoviocytes significantly
inhibits subsequent stimulation by IL-1 in vitro. Since GFAT is the rate limiting enzyme in the synthesis of intracellular glucosamine and its
derivatives, these results may open new possibilities for osteoarthritis treatment.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA), the most common articular disorder, is
characterized primarily by the progressive loss of articular
cartilage accompanied by sclerosis of subchondral bone
and the formation of osteophytes1. Although excessive or
traumatic joint loading coupled with genetic predisposition
are considered initiating factors in OA, many investi-
gators consider interleukin-1 (IL-1) and other inflammatory
mediators, synthesized locally by synovial cells and
chondrocytes, to be important in the progression of the
disease2,3. At low levels, IL-1 inhibits proteoglycan and
collagen synthesis by chondrocytes, while at higher con-
centrations, it stimulates increased production of specific
tissue degradating enzymes by chondrocytes and synovial
fibroblasts4–6. These include serine proteases and matrix
metalloproteases, such as collagenase, gelatinase, and
stromelysin7. Moreover, in activated chondrocytes, the pro-
inflammatory effects of this cytokine are amplified by a
variety of downstream mediators such as prostaglandin E2
(PGE2) produced by the induction of cyclo-oxygenase 2, or
nitric oxide (NO) formed by inducible nitric oxide synthase
(iNOS)8,9.
Ideally, successful treatment of OA would not only reduce
or eliminate joint pain, but would also slow or reverse the
loss of articular cartilage. In this respect, present treat-
ments are unsatisfactory. For example, although non-
steroidal anti-inflammatory drugs, the most commonly used
agents in the management of arthritis, improve the quality
of life by diminishing pain and inflammation, they frequently
cause adverse side-effects10,11 and do not modify the
course of the degenerative process.
Preliminary evidence suggests that some slow-acting
drugs such as glucosamine, may exert a favorable influ-
ence on the course of OA12,13. Based on their suspected
protective and stimulatory effects on cartilage, different
formulations, such as glucosamine sulfate and/or chondro-
itin sulfate, are commercially available and widely
touted in the lay press as medications for OA. However,
doubts about the efficacy of these agents persist
among the medical community. Indeed, despite the fact
that glucosamine has been used in clinical trials for more
than a decade14,15, the mechanism by which this amino
sugar might mediate its anti-arthritic effects is unknown
and has only recently become the focus of basic
research16–20.
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In vitro, the addition of glucosamine to culture medium
has been shown to antagonize the effects of IL-1 on
chondrocytes17 and on cartilage explants21. In these exper-
iments, though, extraordinarily high concentrations of glu-
cosamine were required to effectively inhibit the responses
of chondrocytes to IL-1. Achieving similar local concen-
trations in vivo would require the administration of unreal-
istically large quantities of this amino-sugar. It is therefore
unlikely that glucosamine ingested orally could attain an
equivalent level of efficacy within the joint as it does in vitro.
A method by which it may be possible to generate
effective levels of glucosamine in the joint tissues is through
gene transfer. Although glucosamine cannot be synthe-
sized directly as a gene product, it may be possible to
duplicate its effects by increasing the synthesis of glucosa-
mine and glucosamine derivatives in target cells by upregu-
lating the hexosamine pathway. Under normal conditions a
small percentage of glucose that enters the cell is shunted
through the hexosamine pathway for conversion into pre-
cursors of macromolecules based on amino sugars. In the
first step of this pathway, fructose-6-phosphate is con-
verted to glucosamine-6-phosphate by the rate limiting
enzyme glutamine: fructose-6-phosphate amidotransferase
(GFAT)22. Glucosamine-6-phosphate is the metabolite into
which exogenous glucosamine is first converted following
entry into the cell. In recent studies it was shown that
the adenoviral-mediated delivery and overexpression of
GFAT in pancreatic -cells induced biological effects
similar to those observed from treatment with exogenous
glucosamine23.
Because of their ease of production and application to
joint tissues24,25, recombinant adenoviral vectors were
selected as a vehicle for gene delivery for use in this in vitro
study. Vectors based on this system have been shown
to transduce with high efficiency numerous cell types
including monolayer cultures of synoviocytes and
chondrocytes26–28. Unfortunately, efficient transduction of
chondrocytes within the dense extra-cellular matrix of car-
tilage is not presently achievable. Indeed, following direct
injection of a recombinant vector, the vast majority of gene
transfer occurs within the cells of the synovial lining. Thus,
to simulate in vitro the process of direct intra-articular gene
transfer, we established a system whereby alginate beads
seeded with chondrocytes were co-cultured with synovial
fibroblasts previously infected with an adenoviral vector
carrying the cDNA for GFAT. The responses of the various
cell types to IL-1 stimulation were then measured.
The present study was designed to explore the feasibility
of this approach as a possible mean of antagonizing the
chondrodegenerative effects of IL-1. Our results provide
evidence that overexpression of GFAT in synovial cells may
achieve a level of protection from IL-1 stimulation similar to
that observed previously by addition of glucosamine in
culture medium17.
Materials and methods
RECOMBINANT ADENOVIRUS
The adenoviral vector containing the cDNA green fluor-
escent protein (Ad.GFP) originated from replication-
deficient type 5 adenovirus lacking E1 and E3 loci. The
GFP cDNA was inserted into an expression cassette in the
E1 region driven by the human cytomegalovirus (CMV)
early promoter29. To enable expression of both GFP and
GFAT from a single adenovirus (Ad.GFAT/GFP)23, a vector
was constructed using the AdEasy system (Stratagene)30,
such that the GFAT coding region was inserted down-
stream of that for GFP. An internal ribosome entry
site contained between the two coding regions permits
expression of both gene products from a single poly-
cistronic message. Expression of this construct is also
driven by the CMV promoter. Suspensions of recombinant
adenovirus were prepared by amplification in 293 cells
followed by purification using three consecutive CsCl
gradients by established methods31. Viral titers were esti-
mated by optical density at 260 nm and standard plaque
assay.
CHONDROCYTE ISOLATION AND CULTURE
Articular chondrocytes were isolated from the femoral
head caps of Wistar male rats under aseptic conditions
(Charles River Laboratories). Chondrocytes were obtained
by sequential digestion of the cartilage with pronase and
type II collagenase (Life Technologies) as previously
described32 and then cultured in 25-cm2 flasks in complete
Dulbecco’s Modified Eagle Medium Ham’s F12 ([DMEM/
Ham’s F-12] supplemented with 10% fetal bovine serum
and 1% penicillin-streptomycin [Life Technologies]) at 37°C
in a humidified atmosphere containing 5% CO2. At conflu-
ence, the chondrocytes were encapsulated in alginate
beads at a concentration of 2×106 cells/ml [low viscosity
alginate (1.2%, w/v) (from Macrocystis pyrifera, Sigma)]33.
Beads were maintained in complete DMEM/Ham’s F-12 for
10 days in a humidified atmosphere with 5% CO2 at 37°C
before further experiments.
SYNOVIOCYTE ISOLATION AND CULTURE
Synovial cells were isolated from the synovial mem-
branes of the knees of Wistar rats. Following sequential
pronase/collagenase digestion, synovial cells were isolated
and adherent type B synoviocytes cultured as previously
described34. The synovial fibroblasts were trypsinized and
counted; 1/3 of the cells were transduced with Ad.GFAT/
GFP, and 1/3 were transduced with Ad.GFP as a control
for viral infection. The remaining 1/3 of the cells were
not transduced. Unmodified, Ad.GFAT/GFP and Ad.GFP
synoviocytes were then seeded at a density of 4×105 cells
per well in 12 well plates and cultured in 1 ml of complete
DMEM/Ham’s F-12. Twenty-four hours later, co-cultures
were established by addition of two alginate beads contain-
ing chondrocytes to each well. After 24 h, the co-cultures
were challenged by the addition of human IL-1 (R&D
system) at 0, 1, 5, or 10 ng/ml in 1 ml of complete medium.
Twenty-four hours after addition of IL-1, the cultures were
analyzed for evidence of cytokine stimulation.
HUMAN GFAT mRNA EXPRESSION
At approximately 90% confluence in 25-cm2 flasks, indi-
vidual cultures of rat synoviocytes were infected using a
range of doses of Ad.GFAT/GFP (0 to 400 multiplicity of
infection [MOI]) for 4 h in Gey’s balanced solution (Life
Technologies). Forty eight hours after transduction, total
RNA was isolated from cell cultures by guanidinium thio-
cyanate; phenol:chloroform extraction using Trizol (Life
Technologies) according to the manufacturer’s protocol.
The recovered RNA was quantified by spectrophotometry
at 260/280 nm. The relative levels of GFAT and GAPDH
mRNA were measured using RT-PCR. Total RNA was first
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heated to 65°C for 10 min and placed on ice. Reverse
transcription was performed in a final volume of 20 µl using
100 pmol of a hexamer random primer, 200 µM of each
dNTP, 40 units of RNase OUT and 200 units of MML-V
RNase H- reverse transcriptase (Life technologies) (37°C
1 hr, 95°C 5 min). For PCR amplification, 2 µl of the RT
reaction products were mixed in 50 µl with 200 µM of each
dNTP, 20 pmol of sequence specific primers (MWG) and 2
units of Taq DNA polymerase (Life technologies). For
amplification of human GFAT (32 cycles [45 s 95°C, 45 s
60°C, 45 s 72°C]), the forward primer extended from
nucleotide 69 to 92, and the reverse primer was comp-
lementary to sequences at positions 877 to 900, in accord-
ance with the human sequence (GenBank accession
number M90516). To avoid quantitation of rat endogenous
GFAT, amplification products were distinguished using
restriction site polymorphism: a single recognition
sequence for Bam HI in the rat GFAT amplification product
permitted digestion into 2 fragments (253 and 613 bp),
while the human product which does not contain this site
remained uncut. For amplification of rat GAPDH (32 cycles
[45 s 95°C, 45 s 65°C, 45 s 72°C]), the forward primer
extended from nucleotides 758 to 781 and the reverse
primer was complementary to nucleotides 983 to 1010,
based upon the rat sequence (GenBank accession number
AF106860). PCR products were then analysed during
exponential phase of amplification. Following BamHI endo-
nuclease digestion where appropriate, RT-PCR products
were resolved by agarose gel electrophoresis (1.6%) and
stained with ethidium bromide. DNA bands were visualized
under UV light, photographed and quantitated by densito-
metric analysis with Scion Image software (NIH Image).
After normalization of the RT-PCR products to GAPDH,
GFAT levels were expressed relative to that observed at
the lowest viral dose.
MEASUREMENT OF PROTEOGLYCAN SYNTHESIS
Following IL-1 treatment, alginate beads were removed
from co-culture and incubated for 4 h in complete DMEM/
Ham’s F-12 medium supplemented with 10 µCi/ml of
Na235SO4. The beads were then extensively washed with
0.15 M NaCl and solubilized overnight in Soluene-350
(0.5 M quaternary ammonium hydroxide in toluene). The
amount of radiolabeled sulfate incorporated into newly
synthesized glycosaminoglycans was quantitated by liquid
scintillation counting35,36.
NITRITE ASSAY
NO production was determined spectrophotometrically
by measuring the accumulation of nitrite (NO-2), a stable
breakdown product of NO, in harvested culture medium by
the Griess reaction using sodium nitrite as a standard37.
Briefly, 100 µl of culture supernatant were mixed with 100 µl
of Griess reagent (sulfanilamide (1% [w/v]) in 2.5% H3PO4
and N-naphthylethylenediamine dihydrochoride (0.1%
[w/v]) in H2O) for 5 min in 96-well plates. The absorbance at
550 nm was measured on a MR5000 microplate reader.
Nitrite concentration was calculated from a standard curve
of sodium nitrite. Results are expressed in µM.
PGE2 ASSAY
PGE2 released by the chondrocytes and the synovio-
cytes was measured in conditioned media by specific
ELISA according to the manufacturer’s instructions (R&D
System). This assay does not cross-react with other
prostanoids. Results are expressed in ng/ml.
STATISTICAL ANALYSIS
After comparison of data by analysis of variance, differ-
ent groups were compared using Fisher’s t-test. Assays
were made in triplicate. P values less than 0.05 were
considered significant.
Results
GFAT TRANSGENE EXPRESSION IN TRANSDUCED RAT
SYNOVIOCYTES
To determine a working viral dose for our subsequent
experiments, individual cultures of rat synoviocytes were
infected with a range of doses of Ad.GFAT/GFP spanning
approximate multiplicities of infection (MOI) from 0 to 400.
Because this vector enables simultaneous expression of
both GFAT and GFP, we were able to visualize the percent-
age of cells transduced with each viral dose (Fig. 1A). This
is especially important since there is no existing quanti-
tative assay for GFAT protein. Human GFAT expression at
the mRNA level, following transduction with various MOI of
Ad.GFAT/GFP, was determined by semi-quantitative RT-
PCR. For this, 48 h after infection, total RNA was extracted,
and RT-PCR was performed to measure the expression of
human GFAT mRNA at each viral dose relative to that of
GAPDH (Fig. 1B, C). As shown in Fig. 1, from 100 to
400 MOI, nearly 100% of the synovial cells appeared to be
transduced as shown by the number of fluorescent cells
(Fig. 1A), and human GFAT mRNA expression reached its
maximal value (Fig. 1B, 1D). All subsequent experiments
were thus performed using a viral dose of 100 MOI of
Ad.GFAT/GFP.
EFFECT OF Ad.GFAT/GFP TRANSDUCED SYNOVIOCYTES ON IL-1
MEDIATED INHIBITION OF CHONDROCYTE PROTEOGLYCAN
SYNTHESIS
To test if overexpression of GFAT in synoviocytes can
block the effects of IL-1 stimulation of chondrocytes in a
three dimensional matrix, chondrocytes encapsulated in
alginate beads were co-cultured for 24 h with 4×105
untransduced synoviocytes, or synoviocytes transduced
with Ad.GFAT/GFP, or Ad.GFP as a control for viral trans-
duction. Co-cultures were then challenged with 0, 1, 5 or
10 ng/ml IL-1, and proteoglycan synthesis within the
beads was measured 24 h later.
As expected, relative to control, IL-1 treatment of the
cultures containing untransduced synoviocytes decreased
proteoglycan synthesis of the chondrocytes in co-culture by
28% at 1 ng/ml, 36% at 5 ng/ml, and 44% at 10 ng/ml of the
cytokine (Fig. 2). Similar reductions were observed in
chondrocytes co-cultured with synoviocytes transduced
with Ad.GFP. Remarkably, the inhibitory effect of IL-1 on
proteoglycan synthesis in chondrocytes was fully blocked
by co-culture with synoviocytes overexpressing GFAT, even
at 10 ng/ml of IL-1.
EFFECT OF Ad.GFAT/GFP TRANSDUCED SYNOVIOCYTES ON IL-1
MEDIATED STIMULATION OF NO AND PGE2 SYNTHESIS
To investigate further the influence of GFAT over-
expression in synovial fibroblasts on the effects of IL-1 in
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the co-cultures, we examined the NO and PGE2 levels in
the conditioned media from the previous experiments. In
the absence of IL-1 treatment, the untransduced and
adenoviraly infected co-culture systems showed similar
baseline levels of NO production of approximately 4 µM
(Fig. 3A). In the co-cultures with unmodified synovial fibro-
blasts and those transduced with Ad.GFP, NO levels were
found to increase with the amount of IL-1 added and
at highest dose reached a maximum of 21 and 20 µM,
respectively. Interestingly, co-culture of chondrocytes with
synovial fibroblasts transduced to overexpress GFAT
strongly reduced NO production in response to IL-1.
Indeed, full inhibition was observed when cells were chal-
lenged with the lowest dose of IL-1 and only a slight
increase to 5.5 and 7 µM was detected in the presence of 5
and 10 ng/ml of IL-1 respectively.
PGE2 levels in the conditioned media were measured
by specific ELISA. As shown in Fig. 3B, IL-1 strongly
increased PGE2 production when the chondrocyte beads
were co-cultured with normal synoviocytes (up to 850 ng/ml
for 10 ng/ml of IL-1) or Ad.GFP transduced synoviocytes
(up to 767 ng/ml at 10 ng/ml of IL-1). However, the pres-
ence of synovial cells overexpressing GFAT reduced PGE2
production at all doses of IL-1. The highest dose of IL-1
produced 163 ng/ml of PGE2, corresponding to an 80%
decrease vs co-culture using normal synoviocytes.
To provide an indication of the proportion of NO and
PGE2 produced by each cell type in the co-culture system,
chondrocyte beads or untransduced synoviocytes were
cultured separately. NO and PGE2 levels were then
measured in media conditioned by the respective cultures
with or without IL-1 challenge at 10 ng/ml. As shown in
Fig. 4A, following IL-1 stimulation, chondrocytes produced
5.5 µM and synoviocytes 12.33 µM of NO, which represent
26 and 59%, respectively of the total NO production in a
co-culture system (21 µM). Analyses of the same con-
ditioned media also showed that chondrocytes produced
148 ng/ml and synovial fibroblasts 622 ng/ml of PGE2,
which represent 17% and 73%, respectively of the total
PGE2 production in a co-culture system (850 ng/ml) (Fig.
4B).
Discussion
In this study, synovial fibroblasts were genetically modi-
fied with an adenovirus carrying the cDNA for GFAT and
then were co-cultured with chondrocytes encapsulated in
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Fig. 1. Transgene expression in synovial fibroblast following transduction with Ad.GFAT/GFP. Primary cultures of synovial fibroblasts were
grown to confluence in 25-cm2 flasks and infected with different doses of an adenovirus carrying cDNA for both GFAT and GFP. Two days
after infection, GFP expression was visualized under fluorescent microscopy (A), total RNA was then extracted and GFAT and GAPDH
mRNA expression were analyzed by RT-PCR. Electrophoretic profiles of GFAT (B) and GAPDH (C) RT-PCR products for each dose of
adenovirus are shown. Using scanning densitometry analysis of RT-PCR products illustrated in (B) and (C), respective GFAT products were
normalized to GAPDH. The levels of GFAT products were then plotted relative to that obtained at an MOI of 2 (D).
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alginate beads. Since the primary site of gene transfer
following direct intra-articular injection of a recombinant
vector occurs in the synovial lining, this co-culture system
was designed to test the practical application of GFAT gene
delivery by simulating the physical separation of the
chondrocytes sequestered in cartilage matrix from trans-
duced synoviocytes in vivo. In this in vitro system, over-
expression of GFAT in synoviocytes antagonized the
effects of IL-1 on the co-culture system. The level of
inhibition was similar to that observed when chondrocytes
were cultured in the presence of high concentrations
(20 mM) of exogenous glucosamine17. Indeed, as well as
relieving the inhibition of proteoglycan synthesis in
chondrocytes, overexpression of GFAT in synovial cells
almost totally suppressed IL-1-mediated increases in NO
and PGE2 production, suggesting an inhibition of their
synthesis by both synovial fibroblasts and chondrocytes in
the co-culture system.
Although our results do not identify the biological mech-
anism involved in the protection against IL-1, they implicate
involvement of a soluble mediator. GFAT is a key enzyme in
the hexosamine pathway, which within the cell catalyzes
the synthesis of glucosamine and other precursors of
macromolecules based on this amino-sugar. Thus,
although the genetically modified synovial cells may have
increased levels of intracellular glucosamine-6-phosphate,
the production of other glucosamine derivatives may
also be increased. It is therefore possible that GFAT
overexpression in synoviocytes is capable of activating
multiple protective pathways in responsive cells. Our pre-
vious data18 identifying nuclear factor-B activation as
a target of glucosamine action are consistent with this
suggestion. In the present system, IL-1 stimulation of
chondrocytes was blocked by exposure to synoviocytes
genetically modified to overexpress GFAT. This suggests
that glucosamine and/or downstream cellular products
arising from overproduction of GFAT would have first
to diffuse from the modified synoviocytes to inhibit the
response of the chondrocytes to IL-1. Specific exper-
iments to elucidate the mechanism are currently underway.
In vitro, glucosamine-mediated inhibition of IL-1 required
high concentrations that may be unachievable by oral
administration, as most glucosamine formulations do not
surpass 1.5 g per day. An additional disadvantage of the
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Fig. 2. Effect of Ad.GFAT/GFP transduced synoviocytes on IL-1
mediated inhibition of chondrocyte proteoglycan synthesis.
Chondrocytes encapsulated in alginate beads were co-cultured
with untransduced synovial fibroblasts or those infected with either
Ad.GFAT/GFP or Ad.GFP in complete medium for 24 h. IL-1 was
then added to individual culture at 0 ng/ml; 1 ng/ml; 5 ng/ml; or
10 ng/ml. Twenty-four hours later, proteoglycan synthesis was
evaluated by incorporation of radiolabeled sodium sulfate. Results
are expressed in cpm (each bar represents the mean of three
assays. Error bars represent one S.D.). *, P<0.05 versus untrans-
duced control by Fisher’s t-test.
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Fig. 3. Effect of GFAT overexpression on IL-1 mediated stimula-
tion of NO and PGE2 production. Chondrocytes encapsulated in
alginate beads were co-cultured for 24 h with untransduced syno-
vial fibroblasts or those infected with either Ad.GFAT/GFP or
Ad.GFP. IL-1 was then added to individual cultures at 0; 1; 5; or
10 ng/ml. Twenty-four hours later, NO production was assessed in
the conditioned media by measurement of nitrite (A). Results are
expressed in µM nitrite. PGE2 concentrations (B) were also deter-
mined by ELISA in the medium. Results are expressed in ng/ml
PGE2 Each bar represents the mean of three assays. Error bars
represent one S.D. *, P<0.05 vs untransduced control, #, P<0.05
versus Ad.GFP control by Fisher’s t-test.
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oral administration of glucosamine is the possibility of
inducing insulin resistance and other systemic effects.
Intra-articular gene delivery may offer one strategy for
circumventing this problem. Indeed, by limiting gene trans-
fer to diseased joints, exposure of extra-articular tissues to
the effects of GFAT overexpression would be minimized.
Data from our laboratory have shown that the synovial
lining is capable of maintaining therapeutic levels of trans-
gene expression for several months39, providing optimism
that the use of GFAT gene transfer might be effective in the
treatment of chronic articular disease such as OA. An
appealing aspect to a gene delivery approach such as
this, is that the gene product delivered has no known
immunomodulatory activities, which may reduce potential
side effects, such as increased susceptibility to infection
in contrast to TNF receptors, IL-4 or vIL-1025,38–44. Never-
theless, the effect of long term overproduction of GFAT on
the biology of the synovial lining cells remains unknown.
In conclusion, the results of the present study demon-
strate the feasibility of antagonizing the response of
chondrocytes to IL-1 by transfer of GFAT cDNA to synovial
fibroblasts in vitro and lay the foundation for studies in
animal model to explore the merit of therapeutic application
in OA.
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